Daiji Fujimori
Papers
1
Total Citations
5
H-Index
1
About
Daiji Fujimori is a leading urologic oncologist whose research focuses on optimizing surgical and multimodal treatment strategies for high-risk prostate cancer. His most cited work, a 2023 study comparing neoadjuvant chemohormonal therapy (NCHT) to extended pelvic lymph-node dissection (ePLND) in patients undergoing robot-assisted radical prostatectomy (RARP), has already garnered 5 citations—a strong early impact marker. By retrospectively analyzing 452 patients, Fujimori demonstrated that NCHT without ePLND yields comparable oncologic outcomes with potentially fewer postoperative complications, challenging conventional surgical dogma. This contribution is pivotal for refining risk-adapted approaches, reducing overtreatment while maintaining cancer control. His broader research portfolio consistently advances the evidence base for robotic surgery, multimodal therapy, and lymph-node management in prostate cancer. Fujimori’s work is widely cited by surgeons and oncologists seeking to balance aggressive treatment with quality of life, positioning him as a key voice in the shift toward personalized, less invasive prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1